ACRS Aclaris Therapeutics Inc

Price (delayed)

$8.12

Market cap

$541.55M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.33

Enterprise value

$496.95M

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The ...

Highlights
Aclaris Therapeutics's gross margin has surged by 97% YoY and by 18% QoQ
ACRS's gross profit is up by 49% from the previous quarter
Aclaris Therapeutics's quick ratio has decreased by 21% QoQ but it has increased by 19% YoY
Aclaris Therapeutics's EPS has increased by 17% YoY but it has decreased by 3.1% QoQ
ACRS's equity is down by 10% QoQ

Key stats

What are the main financial stats of ACRS
Market
Shares outstanding
66.69M
Market cap
$541.55M
Enterprise value
$496.95M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.74
Price to sales (P/S)
17.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.7
Earnings
Revenue
$29.75M
EBIT
-$86.91M
EBITDA
-$86.11M
Free cash flow
-$68.17M
Per share
EPS
-$1.33
Free cash flow per share
-$1.05
Book value per share
$2.96
Revenue per share
$0.46
TBVPS
$3.8
Balance sheet
Total assets
$254.6M
Total liabilities
$56.98M
Debt
$684,000
Equity
$197.62M
Working capital
$209.61M
Liquidity
Debt to equity
0
Current ratio
10.55
Quick ratio
9.94
Net debt/EBITDA
0.52
Margins
EBITDA margin
-289.4%
Gross margin
59.8%
Net margin
-292.1%
Operating margin
-286.2%
Efficiency
Return on assets
-33.9%
Return on equity
-41.7%
Return on invested capital
-48.6%
Return on capital employed
-37.4%
Return on sales
-292.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACRS stock price

How has the Aclaris Therapeutics stock price performed over time
Intraday
-1.46%
1 week
1.63%
1 month
-36.01%
1 year
-52.93%
YTD
-48.44%
QTD
-48.44%

Financial performance

How have Aclaris Therapeutics's revenue and profit performed over time
Revenue
$29.75M
Gross profit
$17.79M
Operating income
-$85.15M
Net income
-$86.91M
Gross margin
59.8%
Net margin
-292.1%
Aclaris Therapeutics's gross margin has surged by 97% YoY and by 18% QoQ
ACRS's net margin has soared by 78% YoY and by 16% from the previous quarter
Aclaris Therapeutics's operating margin has soared by 70% YoY and by 20% from the previous quarter
ACRS's gross profit is up by 49% from the previous quarter

Growth

What is Aclaris Therapeutics's growth rate over time

Valuation

What is Aclaris Therapeutics stock price valuation
P/E
N/A
P/B
2.74
P/S
17.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.7
Aclaris Therapeutics's EPS has increased by 17% YoY but it has decreased by 3.1% QoQ
ACRS's P/B is 44% below its last 4 quarters average of 5.0 and 23% below its 5-year quarterly average of 3.6
ACRS's equity is down by 10% QoQ
ACRS's P/S is 82% below its last 4 quarters average of 98.4 and 77% below its 5-year quarterly average of 77.9
The company's revenue rose by 27% QoQ

Efficiency

How efficient is Aclaris Therapeutics business performance
Aclaris Therapeutics's return on sales has surged by 78% YoY and by 16% QoQ
The company's return on equity rose by 13% YoY but it fell by 6% QoQ
Aclaris Therapeutics's return on invested capital has increased by 12% YoY but it has decreased by 8% QoQ
The ROA has increased by 10% YoY but it has decreased by 6% from the previous quarter

Dividends

What is ACRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACRS.

Financial health

How did Aclaris Therapeutics financials performed over time
Aclaris Therapeutics's quick ratio has decreased by 21% QoQ but it has increased by 19% YoY
ACRS's current ratio is down by 19% since the previous quarter but it is up by 18% year-on-year
ACRS's debt is 100% less than its equity
ACRS's debt is down by 11% from the previous quarter
ACRS's equity is down by 10% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.